Dividends & Income
To screen ETFs by asset class, performance, yield and more, check out the
Author Following Options:
Follow this author
See their articles on your Seeking Alpha homepage and in your feed.
Real-time alerts on this author
Get their new articles emailed to you as they are published.
Daily digest on all my authors
Get all your favorite authors’ new articles emailed to you in one daily digest.
View as an RSS Feed
Biologic Drugs: A Fast Growing Industry In The Making
I realize Remicade is not the sales champ - what I was getting at in the article had more to do with its ad campaign and the fact that it is now practically a household name.
I think whether or not the mouse protein is at the heart of the problem is up for debate, but I have spoken with several GI's and other doctors, and the facts are that reactions to Remicade have become an increasing problem in recent years, and that Humira and Cimzia have lower reaction rates.
I appreciate your taking the time to comment.
Nov 30, 2011. 09:47 AM
Link to Comment
Xignite quote data
© 2015 Seeking Alpha